Search results
Results from the WOW.Com Content Network
When used as a delivery system, the ability to induce instability in the construct is commonly exploited allowing the selective release of the encapsulated therapeutic agent in close proximity to the target tissue/cell in vivo. This nanocarrier system is commonly used in anti-cancer treatments as the acidity of the tumour mass caused by an over ...
The Journal of Antibiotics is a peer-reviewed medical journal published by the Nature Publishing Group for the Japan Antibiotics Research Association.. The journal seeks to endorse studies on antibiotics and associated types of biologically-active substances.
ATC code J01 Antibacterials for systemic use is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.
Thin-film drug delivery uses a dissolving film or oral drug strip to administer drugs via absorption in the mouth (buccally or sublingually) and/or via the small intestines (enterically). A film is prepared using hydrophilic polymers that rapidly dissolves on the tongue or buccal cavity, delivering the drug to the systemic circulation via ...
[159] [160] According to the WHO fifty one new therapeutic entities - antibiotics (including combinations), are in phase 1–3 clinical trials as of May 2017. [157] Antibiotics targeting multidrug-resistant Gram-positive pathogens remains a high priority. [161] [157] A few antibiotics have received marketing authorization in the last seven years.
Drug Delivery is a peer-reviewed open access medical journal covering research on all aspects of drug delivery, a core aspect of drug development. It is published by Taylor & Francis and since 2009 the editor-in-chief is Vladimir Torchilin. Biochemist Alfred Stracher founded the journal in 1997 and was its editor-in-chief until his death in ...
Their targeting ability was believed to limit side effects for cancer patients and to give a wider therapeutic window than other chemotherapeutic agents, although this promise hasn't yet been realized in the clinic. [7] ADC technologies have been featured in many publications, [8] [9] including scientific journals.